Recent disclosures in the Pan-KRAS field have revealed a set of data worthy of close examination. JACOBIO-B (01167) announced Phase I study results for JAB-23E73 in pancreatic cancer patients. The dose-escalation trial provided safety data from 42 patients, while the efficacy cohort of 13 KRAS-mutated pancreatic cancer patients was reported for the 160mg and higher dose groups. This marks the first clinical Phase I data disclosure for a small molecule Pan-KRAS inhibitor. Although not the complete Phase I dataset, it represents the most extensive clinical data publicly available to date from any company developing such inhibitors globally, allowing for preliminary comparisons with Revolution Medicines' Phase III molecular glue candidate RMC-6236 (a pan-Ras, not pan-KRAS, inhibitor).

The disclosed safety profile for JAB-23E73 comes from 42 patients. Grade 3 treatment-related adverse events occurred in 11.9% of patients, with no observed Grade 4 or 5 events. Furthermore, no Grade 3 or higher gastrointestinal toxicities were reported. In contrast, RMC-6236 reported Grade 3 or higher treatment-related adverse events in 34% of patients as a single agent in second-line-plus settings, making JAB-23E73's rate of 11.9% approximately one-third that of its competitor. Safety has been a major challenge in developing pan-RAS inhibitors. Common adverse events for RMC-6236 in public data include rash. JACOBIO-B's candidate demonstrates notably lower skin toxicity, with no Grade 3 or higher events. A distinct characteristic observed with JAB-23E73 is its very low gastrointestinal toxicity. If this safety profile holds in subsequent trials, its potential in combination with chemotherapy could be significantly greater. While hematological and hepatorenal toxicity data for JAB-23E73 were not specifically disclosed, the overall low rate of Grade 3 adverse events (11.9%) suggests these toxicities are unlikely to be high. RMC-6236's Grade 3 hematological and hepatorenal toxicities range from 4% to 7%; overall, JAB-23E73 appears to have a superior safety profile.

The efficacy of JAB-23E73 has been a key industry focus, as no company had previously disclosed treatment effect data for a small molecule Pan-KRAS inhibitor. In the 160mg+ cohort, among 13 evaluable KRAS-mutated pancreatic cancer patients, 2 were in second-line treatment, and the remaining 11 were in third-line or later settings. This represents a heavily pre-treated patient population, likely due to physician caution during the Phase I trial. While lung cancer data often combines second-line and later results, outcomes differ significantly between second-line and third-line-plus treatments in pancreatic cancer, prompting most companies to report them separately. In this combined group of 13 patients, the objective response rate was 38.5% (5/13), and the disease control rate was 84.6% (11/13). The small sample size is an initial consideration, but the patient line structure adds substantial weight to these results when compared to competitor data.

For RMC-6236 in pancreatic cancer: the ORR is approximately 29% in second-line (RAS mutant) and about 22% in third-line-plus settings. RMC-6236 reports these lines separately, making direct head-to-head comparison difficult. JACOBIO-B likely combined its data due to the small number of second-line patients (only 2). The specific response count for these two second-line patients was not provided, leading to interesting hypothetical comparisons. Scenario 1: If 1 of the 2 second-line patients achieved a partial response, JACOBIO's ORR would be significantly higher than RMC-6236's in both second-line (50% vs. 29%) and third-line-plus (36% vs. 22%). Scenario 2: If both second-line patients responded, the ORR would still be higher in second-line (100% vs. 29%) and comparable or slightly higher in third-line-plus (27% vs. 22%). With only two second-line patients, definitive conclusions on efficacy cannot be drawn for that subgroup. However, based on the 11 third-line-plus patients, JAB-23E73's observed ORR (either 27% or 36% depending on the second-line outcome) exceeds RMC-6236's 22% in third-line patients and is even comparable to or higher than its 29% in second-line. While the sample size remains small, it indicates that JAB-23E73 already demonstrates efficacy signals not inferior to RMC-6236.

A recent regulatory decision further underscores this potential. China's Center for Drug Evaluation has approved JAB-23E73 to proceed directly into a Phase Ib/III trial in combination with gemcitabine and nab-paclitaxel for first-line treatment of KRAS-mutated pancreatic cancer. This accelerated development pathway is notable; many first-in-class small molecules typically start in second or third-line settings. An early move into first-line combination therapy often indicates regulatory recognition of a candidate's safety and early efficacy signals.

Broadening the perspective, the core logic of the Pan-KRAS field is straightforward. KRAS is one of the most important driver genes in oncology, with mutations implicated in approximately one-quarter of all solid tumors, including pancreatic cancer (~90%), colorectal cancer (~50%), and non-small cell lung cancer (~30%). A successful Pan-KRAS inhibitor capable of targeting multiple KRAS mutant subtypes theoretically addresses a market comprising several major cancer indications. This vast potential underpins the high valuations already seen in the global Pan-KRAS space. Revolution Medicines, with RMC-6236 as its core asset and a market capitalization near $20 billion, is a prime example, essentially betting its value on this single pipeline. In contrast, JACOBIO-B currently holds a market cap of approximately HKD $5 billion (around $600-700 million). Based on market capitalization alone, the gap is nearly twentyfold. Factors such as Revolution's US listing, greater liquidity, and more mature data contribute to this disparity. However, if JAB-23E73 continues to report positive data maintaining similar efficacy and safety in larger sample sizes, the competitive landscape may not remain a one-horse race.

For investors, several upcoming milestones will be critical: first, the release of larger-sample clinical data for JAB-23E73; second, progress in the first-line pancreatic cancer combination trial; and third, the potential emergence of future head-to-head competition within the Pan-KRAS arena. Over the past year, the Pan-(K)RAS field was largely perceived as dominated by RMC-6236. With the gradual disclosure of JAB-23E73's data, new variables are entering the scene. The story of Pan-KRAS inhibitors may just be beginning.